Regeneron showcases advances across oncology portfolio and pipeline at esmo, highlighting novel and patient-focused approach for difficult-to-treat cancers

New safety and pharmacokinetic data from phase 3 c-post trial provide insights on an every 6-week dosing regimen of adjuvant libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma new safety and pharmacokinetic data from phase 3 c-post trial provide insights on an every 6-week dosing regimen of adjuvant libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma
REGN Ratings Summary
REGN Quant Ranking